These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31104297)
1. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease. Schubert D; Kepchia D; Liang Z; Dargusch R; Goldberg J; Maher P Mol Neurobiol; 2019 Nov; 56(11):7719-7730. PubMed ID: 31104297 [TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases. Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005 [TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease across a Decade of Research. Tyrakis P; Agridi C; Kourti M Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201317 [TBL] [Abstract][Full Text] [Related]
4. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830 [TBL] [Abstract][Full Text] [Related]
5. Impact of the Cannabinoid System in Alzheimer's Disease. Li S; Huang Y; Yu L; Ji X; Wu J Curr Neuropharmacol; 2023; 21(3):715-726. PubMed ID: 35105293 [TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease; taking the edge off with cannabinoids? Campbell VA; Gowran A Br J Pharmacol; 2007 Nov; 152(5):655-62. PubMed ID: 17828287 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. Marsicano G; Moosmann B; Hermann H; Lutz B; Behl C J Neurochem; 2002 Feb; 80(3):448-56. PubMed ID: 11905991 [TBL] [Abstract][Full Text] [Related]
9. The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer's Disease-like Mouse Model. Kim J; Choi P; Park YT; Kim T; Ham J; Kim JC Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047798 [TBL] [Abstract][Full Text] [Related]
10. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. Sánchez Montero JM; Agis-Torres A; Solano D; Söllhuber M; Fernandez M; Villaro W; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Egea J; Martín MI; Girón R Eur J Pharmacol; 2021 Mar; 895():173875. PubMed ID: 33460612 [TBL] [Abstract][Full Text] [Related]
11. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease. Singh YP; Rai H; Singh G; Singh GK; Mishra S; Kumar S; Srikrishna S; Modi G Eur J Med Chem; 2021 Apr; 215():113278. PubMed ID: 33662757 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoids in late-onset Alzheimer's disease. Ahmed A; van der Marck MA; van den Elsen G; Olde Rikkert M Clin Pharmacol Ther; 2015 Jun; 97(6):597-606. PubMed ID: 25788394 [TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of the cannabinoids in neuroprotection. Grundy RI Expert Opin Investig Drugs; 2002 Oct; 11(10):1365-74. PubMed ID: 12387700 [TBL] [Abstract][Full Text] [Related]
14. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Harvey BS; Ohlsson KS; Mååg JL; Musgrave IF; Smid SD Neurotoxicology; 2012 Jan; 33(1):138-46. PubMed ID: 22233683 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review. Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Rosenberg EC; Patra PH; Whalley BJ Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698 [TBL] [Abstract][Full Text] [Related]
17. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pertwee RG Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283 [TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in depressive disorders. Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]